featured
Surufatinib in Advanced Extrapancreatic Neuroendocrine Tumors
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Surufatinib in Advanced Extrapancreatic Neuroendocrine Tumours (SANET-ep): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study
Lancet Oncol 2020 Sep 18;[EPub Ahead of Print], J Xu, L Shen, Z Zhou, J Li, C Bai, Y Chi, Z Li, N Xu, E Li, T Liu, Y Bai, Y Yuan, X Li, X Wang, J Chen, J Ying, X Yu, S Qin, X Yuan, T Zhang, Y Deng, D Xiu, Y Cheng, M Tao, R Jia, W Wang, J Li, S Fan, M Peng, W SuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.